Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 9,669 shares of the business's stock in a transaction on Tuesday, December 27th. The shares were sold at an average price of $15.02, for a total transaction of $145,228.38. Following the sale, the chief executive officer now directly owns 173,166 shares of the company's stock, valued at approximately $2,600,953.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Dipal Doshi also recently made the following trade(s):
Get Entrada Therapeutics alerts:- On Thursday, December 29th, Dipal Doshi sold 400 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.01, for a total transaction of $6,004.00.
- On Monday, November 28th, Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.91, for a total transaction of $27,820.00.
- On Thursday, October 27th, Dipal Doshi sold 2,000 shares of Entrada Therapeutics stock. The stock was sold at an average price of $21.66, for a total transaction of $43,320.00.
- On Monday, October 24th, Dipal Doshi sold 2,342 shares of Entrada Therapeutics stock. The stock was sold at an average price of $19.30, for a total transaction of $45,200.60.
- On Thursday, October 20th, Dipal Doshi sold 811 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.01, for a total transaction of $14,606.11.
Entrada Therapeutics Stock Down 4.2 %
TRDA opened at $13.52 on Friday. The firm has a 50-day simple moving average of $18.00 and a two-hundred day simple moving average of $14.61. Entrada Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $24.38. The company has a market capitalization of $424.61 million, a PE ratio of -4.33 and a beta of -0.95.
Entrada Therapeutics (NASDAQ:TRDA – Get Rating) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.80) EPS for the quarter. As a group, sell-side analysts expect that Entrada Therapeutics, Inc. will post -3.08 earnings per share for the current year.Wall Street Analyst Weigh In
Several research analysts recently weighed in on the stock. William Blair reaffirmed an "outperform" rating on shares of Entrada Therapeutics in a report on Friday, October 14th. The Goldman Sachs Group upped their target price on shares of Entrada Therapeutics from $13.00 to $18.00 and gave the stock a "neutral" rating in a report on Tuesday, November 8th.
Institutional Trading of Entrada Therapeutics
Several hedge funds have recently made changes to their positions in the business. Fred Alger Management LLC purchased a new stake in shares of Entrada Therapeutics during the 3rd quarter valued at about $283,000. State Street Corp raised its position in Entrada Therapeutics by 10.3% in the 3rd quarter. State Street Corp now owns 33,294 shares of the company's stock worth $525,000 after purchasing an additional 3,100 shares during the period. Vanguard Group Inc. raised its position in Entrada Therapeutics by 14.1% in the 3rd quarter. Vanguard Group Inc. now owns 870,147 shares of the company's stock worth $13,714,000 after purchasing an additional 107,783 shares during the period. Price T Rowe Associates Inc. MD raised its position in Entrada Therapeutics by 21.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,972,050 shares of the company's stock worth $46,840,000 after purchasing an additional 534,552 shares during the period. Finally, Laurion Capital Management LP raised its position in Entrada Therapeutics by 54.2% in the 3rd quarter. Laurion Capital Management LP now owns 199,066 shares of the company's stock worth $3,137,000 after purchasing an additional 70,000 shares during the period. 78.08% of the stock is currently owned by hedge funds and other institutional investors.
About Entrada Therapeutics
(Get Rating)
Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
Further Reading
- Get a free copy of the StockNews.com research report on Entrada Therapeutics (TRDA)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.